Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Regional blood flow by fractional distribution of indicators.

SAPIRSTEIN LA.

Am J Physiol. 1958 Apr;193(1):161-8. No abstract available.

PMID:
13521003
2.

Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery.

Gehl J, Skovsgaard T, Mir LM.

Biochim Biophys Acta. 2002 Jan 15;1569(1-3):51-8.

PMID:
11853957
3.

Reduced tumor oxygenation by treatment with vinblastine.

Sersa G, Krzic M, Sentjurc M, Ivanusa T, Beravs K, Cemazar M, Auersperg M, Swartz HM.

Cancer Res. 2001 May 15;61(10):4266-71.

4.

Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy.

Cemazar M, Parkins CS, Holder AL, Chaplin DJ, Tozer GM, Sersa G.

Br J Cancer. 2001 Feb;84(4):565-70.

5.

Therapeutic perspectives of in vivo cell electropermeabilization.

Mir LM.

Bioelectrochemistry. 2001 Jan;53(1):1-10. Review.

PMID:
11206915
6.
7.

Response to radioimmunotherapy correlates with tumor pO2 measured by EPR oximetry in human tumor xenografts.

O'Hara JA, Blumenthal RD, Grinberg OY, Demidenko E, Grinberg S, Wilmot CM, Taylor AM, Goldenberg DM, Swartz HM.

Radiat Res. 2001 Mar;155(3):466-73.

PMID:
11182798
8.

Improved skin oxygenation after benzyl nicotinate application in different carriers as measured by EPR oximetry in vivo.

Krzic M, Sentjurc M, Kristl J.

J Control Release. 2001 Jan 29;70(1-2):203-11.

PMID:
11166420
9.

Molecular mechanisms involved in cisplatin cytotoxicity.

Jordan P, Carmo-Fonseca M.

Cell Mol Life Sci. 2000 Aug;57(8-9):1229-35. Review.

PMID:
11028915
10.

Mechanisms of electrochemotherapy.

Mir LM, Orlowski S.

Adv Drug Deliv Rev. 1999 Jan 4;35(1):107-118.

PMID:
10837692
11.

Toxicity of anticancer agents mediated by electroporation in vitro.

Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R.

Anticancer Drugs. 2000 Mar;11(3):201-8.

PMID:
10831279
12.

Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients.

Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z.

Clin Cancer Res. 2000 Mar;6(3):863-7.

13.

Tumor blood flow modifying effect of electrochemotherapy with bleomycin.

Sersa G, Cemazar M, Miklavcic D, Chaplin DJ.

Anticancer Res. 1999 Sep-Oct;19(5B):4017-22.

PMID:
10628347
14.

Tumour blood flow changes induced by application of electric pulses.

Sersa G, Cemazar M, Parkins CS, Chaplin DJ.

Eur J Cancer. 1999 Apr;35(4):672-7.

PMID:
10492645
15.

Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin.

Cemazar M, Miklavcic D, Scancar J, Dolzan V, Golouh R, Sersa G.

Br J Cancer. 1999 Mar;79(9-10):1386-91.

16.

The measurement of oxygen in vivo using EPR techniques.

Swartz HM, Clarkson RB.

Phys Med Biol. 1998 Jul;43(7):1957-75. Review.

PMID:
9703059
17.

Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy.

Mir LM, Glass LF, Sersa G, TeissiƩ J, Domenge C, Miklavcic D, Jaroszeski MJ, Orlowski S, Reintgen DS, Rudolf Z, Belehradek M, Gilbert R, Rols MP, Belehradek J Jr, Bachaud JM, DeConti R, Stabuc B, Cemazar M, Coninx P, Heller R.

Br J Cancer. 1998 Jun;77(12):2336-42.

18.

Electrochemotherapy on liver tumours in rabbits.

Ramirez LH, Orlowski S, An D, Bindoula G, Dzodic R, Ardouin P, Bognel C, Belehradek J Jr, Munck JN, Mir LM.

Br J Cancer. 1998 Jun;77(12):2104-11.

19.

Modification of tumor blood flow: current status and future directions.

Chaplin DJ, Hill SA, Bell KM, Tozer GM.

Semin Radiat Oncol. 1998 Jul;8(3):151-63. Review.

PMID:
9634492
20.

A MRI spatial mapping technique for microvascular permeability and tissue blood volume based on macromolecular contrast agent distribution.

Demsar F, Roberts TP, Schwickert HC, Shames DM, van Dijke CF, Mann JS, Saeed M, Brasch RC.

Magn Reson Med. 1997 Feb;37(2):236-42.

PMID:
9001148

Supplemental Content

Support Center